Retail Cash Prices: What You’d Pay Without Any Coverage
The sticker prices for GLP-1 receptor agonists approved for weight management are not an accident. Novo Nordisk and Eli Lilly have priced these drugs at levels that maximize revenue from insured patients while still leaving uninsured patients with limited options. Understanding the pricing structure is the first step to working around it.
Semaglutide (Ozempic, Wegovy, Rybelsus)
Ozempic (subcutaneous injection, approved for type 2 diabetes) carries a retail list price of approximately $935–$1,029/month depending on dose. The 0.5mg dose pen runs lower; the 2mg maintenance dose runs higher. Ozempic pens are sold as 4-injection packs (one month of supply at weekly dosing).
Wegovy (higher-dose semaglutide, 2.4mg, approved specifically for chronic weight management) carries a retail list price of approximately $1,349/month. Because it is approved for obesity rather than diabetes, coverage criteria differ substantially—and are generally stricter.
Rybelsus (oral semaglutide for type 2 diabetes) runs approximately $850–$935/month. It is not approved for obesity and is not a direct substitute for Wegovy.
Tirzepatide (Mounjaro, Zepbound)
Eli Lilly’s dual GLP-1/GIP agonist is priced comparably. Mounjaro (for type 2 diabetes) lists at approximately $1,023/month. Zepbound (the obesity-approved version) lists at approximately $1,059/month—slightly less expensive than Wegovy at list price, though efficacy data suggests it may outperform semaglutide for weight loss.
Price & Coverage at a Glance
| Drug | Cash Price/Month | With Savings Card | Typical Insurance Criteria | Status |
|---|---|---|---|---|
| Ozempic semaglutide inj. |
$935–$1,029 | $25/mo* | T2D diagnosis; HbA1c ≥7%; prior metformin trial | FDA approved |
| Wegovy semaglutide 2.4mg |
$1,349 | $0/mo* | BMI ≥30 or ≥27 with comorbidity; 6 mo. diet/exercise failure; step therapy varies | FDA approved |
| Mounjaro tirzepatide inj. |
$1,023 | $25/mo* | T2D diagnosis; prior oral agent trial typically required | FDA approved |
| Zepbound tirzepatide 2.5–15mg |
$1,059 | $25–$550/mo* | BMI ≥30 or ≥27 with comorbidity; step therapy common; prior auth required | FDA approved |
| Compounded semaglutide 503A/503B |
$150–$400 | N/A | Not covered by insurance; prescription required | FDA ended shortage exemption |
*Savings cards for commercially insured patients only. Prices as of mid-2025. Cash prices via GoodRx and manufacturer websites; actual pharmacy prices may vary.
Insurance Coverage: How the Criteria Actually Work
Insurance coverage for GLP-1 drugs—especially for obesity indications like Wegovy and Zepbound—is highly variable and often counterintuitive. Understanding the specific clinical criteria your insurer applies is the difference between a $25 copay and a $1,349 monthly bill.
The BMI Threshold Problem
Most commercial plans that cover weight-management GLP-1s require a documented body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one qualifying comorbidity. Qualifying comorbidities typically include: type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease.
BMI thresholds are imperfect. A person with a BMI of 26.5, significant visceral adiposity, and metabolic syndrome may have a stronger clinical case for GLP-1 therapy than a person with a BMI of 31 and no comorbidities—but insurers apply BMI cutoffs rigidly. This is an area where documentation from your physician matters: a letter of medical necessity that explicitly names comorbidities and states a clinical judgment that treatment is indicated can support appeals.
Step Therapy: The Trial-First Requirement
Many plans impose step therapy: you must try and fail a less expensive treatment before the GLP-1 is covered. For weight management, this often means documented participation in a structured weight-loss program for at least 3–6 months with less than 5% weight loss, and sometimes a prior trial of an older weight-loss medication (orlistat, phentermine/topiramate, bupropion/naltrexone).
For diabetes indications, step therapy usually means a documented trial of metformin (and sometimes a second oral agent like an SGLT-2 inhibitor or DPP-4 inhibitor) before a GLP-1 will be covered. If your provider prescribes Ozempic as a first-line agent for type 2 diabetes without documenting metformin intolerance or contraindication, expect a prior authorization denial.
Prior Authorization
Virtually every major commercial insurer requires prior authorization (PA) for GLP-1 medications. Your prescribing physician must submit documentation including: diagnosis codes, current BMI, comorbidities, documentation of lifestyle intervention, and any step therapy completion. PA turnaround is typically 3–15 business days; urgent requests may be processed faster. If denied, you have the right to an appeal—and a peer-to-peer review between your physician and the insurer’s medical director.
Continuous glucose monitors and at-home HbA1c tests let you document baseline metabolic data—useful both for your prescriber and for building a prior authorization case. The iHealth Gluco+ and similar over-the-counter monitors are available without a prescription.
See Options on Amazon →Employer Plan Trends: A Rapidly Shifting Landscape
As of 2024, approximately 50% of large employer-sponsored health plans covered GLP-1 medications for obesity, up from about 25% in 2022. The trend is accelerating but not universal—and the plans that do cover these drugs are implementing increasingly detailed management protocols.
Several major employers including Amazon, JPMorgan Chase, and Ford have added obesity GLP-1 coverage while simultaneously implementing adherence requirements: coverage may be contingent on participation in a concurrent lifestyle intervention program, or may be discontinued if meaningful weight loss (typically 5% body weight at 12 weeks) is not achieved.
On the other side, some large self-insured employers have moved to exclude or cap GLP-1 coverage after seeing substantial cost increases. Shopify and several regional employers dropped weight-management GLP-1 coverage in 2024, citing unsustainable pharmacy benefit spend. This is a live economic tension: GLP-1s reduce long-term cardiovascular and metabolic disease costs, but those savings accrue over 5–10 years while the drug costs hit immediately.
Medicare and Medicaid Coverage Gaps
Medicare Part D: The Obesity Exclusion
This is the most significant coverage gap in the GLP-1 access landscape. Medicare Part D currently does not cover GLP-1 medications prescribed for obesity or weight management. This exclusion dates to a 1990s-era statutory prohibition on Medicare coverage of “agents when used for anorexia, weight loss, or weight gain,” and it applies even to drugs like Wegovy that are specifically approved by the FDA for chronic weight management.
The exception: Medicare will cover GLP-1 drugs when prescribed for type 2 diabetes (Ozempic, Mounjaro) or, more recently, for cardiovascular risk reduction. In 2024, the FDA approved semaglutide (Wegovy) for reducing major adverse cardiovascular events in patients with established cardiovascular disease and obesity—and Medicare covers it under this indication. If you have diagnosed CVD plus obesity, your prescriber may be able to document a cardiovascular indication.
Legislation—the Treat and Reduce Obesity Act—has been introduced in Congress multiple times to remove the Medicare obesity drug exclusion. As of mid-2025, it has not passed, though pressure from patient advocacy groups and the scale of the obesity epidemic has kept it in political discussion.
Medicaid: State-by-State
Medicaid coverage for GLP-1 medications varies by state. As of 2025, most state Medicaid programs do cover GLP-1s for type 2 diabetes (often with step therapy requirements). Coverage for obesity indications is less consistent—states including California, Colorado, and Washington have expanded obesity drug coverage, while many others have not.
If you are on Medicaid and your prescriber wants to prescribe a GLP-1 for weight management, ask your state’s Medicaid program for the current preferred drug list (PDL) and prior authorization requirements. State Medicaid agencies update these regularly.
Compounded Semaglutide: What the FDA Actually Said
Compounded semaglutide became a major market during 2023–2024 when the branded versions were on the FDA drug shortage list. Under FDA regulations, when a drug is on the shortage list, 503A compounding pharmacies (traditional pharmacies compounding for individual patients) and 503B outsourcing facilities (larger-scale compounders supplying to healthcare providers) may compound copies of that drug without infringing on the manufacturer’s exclusivity.
The result was a proliferation of telehealth companies offering compounded semaglutide injections at prices ranging from $150–$400/month—a fraction of branded costs. The quality varied significantly, and the FDA documented multiple adverse event reports, including dosing errors linked to the use of multi-dose vials (the branded drug comes in single-patient, dose-limiting pens).
The February 2025 Ruling
In February 2025, the FDA officially removed semaglutide from the drug shortage list, determining that Novo Nordisk had resolved supply constraints. This removal ended the shortage-based exemption. The FDA issued guidance stating that 503A compounding pharmacies should stop compounding semaglutide products that are essentially copies of the approved drugs.
503B outsourcing facilities were given a longer wind-down window, but the FDA has been clear that their ability to compound semaglutide depends on shortage status, and the shortage has ended. Several telehealth companies that built their business model on compounded semaglutide pivoted, challenged the ruling in court, or began offering patients transition pathways to branded drugs with savings cards.
Manufacturer Savings Cards and Patient Assistance
Novo Nordisk: Ozempic and Wegovy Savings Cards
Novo Nordisk offers savings cards for commercially insured patients—these are not available for patients on Medicare, Medicaid, or other federal programs. The Ozempic Savings Card can reduce monthly cost to $25/month for eligible patients; the Wegovy Savings Card can reduce cost to $0/month for the first 13 months. Both programs have income and insurance eligibility requirements.
Novo Nordisk’s NovoCare Patient Assistance Program provides free medications to uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). Applications are processed through novo-pi.com or by calling the NovoCare line.
Eli Lilly: Mounjaro and Zepbound Savings
Lilly’s Mounjaro Savings Card offers eligible commercially insured patients a reduced copay (as low as $25/month). The Zepbound Savings Card offers commercially insured patients reduced copays; Lilly also launched a direct-to-consumer vial program through LillyDirect that offered Zepbound vials at $399–$549/month for cash-pay patients.
Lilly’s Lilly Cares Patient Assistance Program provides free Mounjaro or Zepbound to qualifying uninsured patients. Eligibility generally requires income below 400% of the federal poverty line and no adequate prescription drug coverage.
State Pharmaceutical Assistance Programs
Some states operate pharmaceutical assistance programs (SPAPs) that supplement Part D coverage for low-income seniors. These vary by state and do not uniformly cover GLP-1 drugs, but they are worth investigating for Medicare-enrolled patients who otherwise face full retail cost.
GLP-1 medications are administered with subcutaneous pen needles. Novo Nordisk and Lilly pens use standard 4mm or 6mm pen needles (32G or 31G). Having the right needle gauge improves comfort at injection. BD and Owen Mumford needles are widely compatible.
Shop Pen Needles on Amazon →-
01
Confirm your diagnosis and BMI documentation
Make sure your chart reflects your current BMI, any comorbidities (diabetes, hypertension, sleep apnea, dyslipidemia, CVD), and your primary diagnosis code. Your prescriber needs to document ICD-10 codes that match your insurer’s coverage criteria before submitting a prior authorization.
-
02
Get your plan’s formulary and PA criteria in writing
Call member services or download your plan’s current formulary document. Confirm whether the specific drug your prescriber wants to prescribe is on-formulary and at what tier, and request the PA criteria form your prescriber must complete.
-
03
Document any step therapy requirements
If your plan requires prior weight-loss intervention, ensure your chart documents structured program participation, duration, and outcomes. If it requires a prior diabetes medication trial, document that history. Missing step therapy documentation is the most common reason for initial PA denials.
-
04
Have your prescriber submit a Letter of Medical Necessity
A strong LMN explicitly states the diagnosis, the clinical rationale for GLP-1 therapy over alternatives, any contraindications to step therapy medications, and the anticipated clinical benefit. Boilerplate LMNs are more likely to be denied than individualized letters.
-
05
Apply for the manufacturer savings card immediately
Even if you expect insurance approval, apply for the savings card before your first fill. If you end up in an appeals process, the card bridges the cost gap. Register at novonordisk-us.com (Ozempic/Wegovy) or lilly.com (Mounjaro/Zepbound).
-
06
If denied, request peer-to-peer review and appeal
You have a right to appeal any PA denial. Your prescriber can request a peer-to-peer review with the insurer’s medical director within the appeal window (typically 60 days of denial). Internal appeal, then external appeal to your state’s independent review organization, are successive options. Include published clinical guidelines (AACE, ADA, STOP Obesity Alliance) supporting the treatment in your appeal documentation.